Therapeutic efficacy of cefozopran in a murine model of haematogenous pneumococcal meningitis.
Antimicrobial regimens for the treatment of pneumococcal meningitis are not established. We have produced a murine model of haematogenous pneumococcal meningitis and have examined its usefulness for determining the required dosage and term of antimicrobial agents. Streptococcus pneumoniae serotype 6 was injected intraperitoneally (inoculum: about 1 x 10(4) CFU) into mice. Although half of the mice died within 2 days, the surviving mice showed positive bacterial cultures, increase of the protein level, decrease of the glucose level and infiltration of polymorphonuclear leucocytes into cerebrospinal fluids (CSF). When cefozopran was administered subcutaneously twice a day for 1-3 days starting 2 days after infection, dose- and duration-dependent effects were observed and all mice treated with 20 mg/kg of cefozopran for 3 days survived. The penetration rate of cefozopran from blood to CSF in infected mice was 44.7%, which was 6 times higher than that obtained in uninfected mice. This model may be useful for investigating the pathogenesis of haematogenous pneumococcal meningitis and its therapy.
Pharmacology Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan. Iizawa_Yuji@takeda.co.jp
Y
Y
Iizawa
K
K
Hiroe
M
M
Nakao
K
K
Okonogi
D000818:Animals; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D008297:Male; D008586:Meningitis, Pneumococcal / Q000097:blood / Q000188:drug therapy*; D051379:Mice; D008813:Mice, Inbred ICR; D016896:Treatment Outcome; D000097586:Cefozopran
D002511:Cephalosporins; D000097586:Cefozopran